Obesity in humans is a major public health crisis worldwide. In addition, livestock species exhibit excessive subcutaneous fat at market weight. However, there are currently few means of reducing adiposity in mammals. This study was conducted with a swine model to test the hypothesis that dietary L-arginine supplementation may increase muscle gain and decrease fat deposition. Twenty-four 110-day-old barrows were assigned randomly into two treatments, representing supplementation with 1.0% L-arginine or 2.05% L-alanine (isonitrogenous control) to a corn- and soybean meal-based diet. Growth performance was measured based on weight gain and food intake. After a 60-day period of supplementation, carcass and muscle composition were measured. Serum triglyceride concentration was 20% lower (P < 0.01) but glucagon level was 36% greater (P < 0.05) in arginine-supplemented than in control pigs. Compared with the control, arginine supplementation increased (P < 0.05) body weight gain by 6.5% and carcass skeletal-muscle content by 5.5%, while decreasing (P < 0.01) carcass fat content by 11%. The arginine treatment enhanced (P < 0.05) longissimus dorsi muscle protein, glycogen, and fat contents by 4.8, 42, and 70%, respectively, as well as muscle pH at 45 min post-mortem by 0.32, while reducing muscle lactate content by 37%. These results support our hypothesis that dietary arginine supplementation beneficially promotes muscle gain and reduces body fat accretion in growing-finishing pigs. The findings have a positive impact on development of novel therapeutics to treat human obesity and enhance swine lean-tissue growth.

Organic solid-state luminescence switching (SLS) materials with the ability to reversibly switch the luminescence by altering the mode of molecular packing without changing the chemical structures of their component molecules have attracted considerable interest in recent years. In this work, we design and synthesize a new class of 2,7diphenylfluorenone derivatives (compounds 1−6) that exhibit prominent aggregation-induced emission (AIE) properties with high solid-state fluorescence quantum yields (29−65%). Among them, 2,7-bis(4-methoxyphenyl)-9H-fluoren-9-one (2) and 2,7-bis(4-ethylphenyl)-9H-fluoren-9-one ( 6) display reversible stimuli-responsive solid-state luminescence switching. Compound 2 transforms between red and yellow crystals (the emission wavelength switches between 601 and 551 nm) under the stimuli of temperature, pressure, or solvent vapor. Similarly, compound 6 exhibits SLS behavior, with luminescence switching between orange (571 nm) and yellow (557 nm). Eight X-ray single-crystal structures, characterization of the photophysical properties, powder X-ray diffraction, and differential scanning calorimetry provide insight into the structure−property relationships of the solid-state fluorescence behavior. The results indicate that the variable solid-state luminescence of the fluorenone derivatives is attributed to the formation of different excimers in different solid phases. Additionally, the stimuli-responsive reversible phase transformations of compounds 2 and 6 involve a structural transition between π−π stacking-directed packing and hydrogen bond-directed packing. The results also demonstrate the feasibility of our design strategy for new solid-state luminescence switching materials: introduction of both π−π stacking and hydrogen bonding into an AIE structure to obtain a metastable solid/crystalline state luminescence system.

No abstract